Report post

Is axs-12 a narcolepsy drug?

AXS-12 has been granted FDA Orphan Drug designation for the treatment of narcolepsy. The product is in phase 3 of development. AXS-12 (reboxetine) is a norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. See clinical and regulatory information.

How long does axs-12 treatment last?

The trial enrolled 68 patients in the 6-month AXS-12 treatment period. Patients (n=42) were then randomized in a 1:1 ratio to continue treatment with AXS-12 or to discontinue AXS-12 and switch to placebo for 3 weeks.

Does axs-12 affect cataplexy attacks?

Patients randomized to switch to placebo experienced a statistically significant worsening in the average weekly number of cataplexy attacks compared with patients randomized to continue AXS-12 treatment, with an increase of 10.29 attacks per week with placebo versus 1.32 with AXS-12, at 3 weeks (p=0.017).

The World's Leading Crypto Trading Platform

Get my welcome gifts